Search for a company

Search for a company

ADXMarket Closed
JULPHAR logo

JULPHAR

Gulf Pharmaceutical Industries

Health Care
AED 1.16
-0.02 (-1.69%)
Bearish
Death cross active

Market Cap

1.3B

P/E Ratio

6.94

sector avg 4.4

Dividend Yield

0.00%

52W Range

1.05 - 1.60

-27.50% from high

Volatility

2.34%

EPS (TTM)

0.17

1D

-1.69%

1W

-1.69%

1M

-7.20%

3M

-9.38%

6M

-20.55%

1Y

-21.62%

Today's Trading

Open

AED 1.18

High

AED 1.18

Low

AED 1.16

Volume

984.1K

Trades

378

Value

AED 7.6M

Chart

Loading chart data...

All prices are split-adjusted

Analysis

As of Jan 9, 2026

Active Signals

Death Cross
Trend

SMA Position

SMA 20
-3.1%
SMA 50
-2.7%
SMA 200
-11.2%

Trend Strength

ADX
16.0Weak trend

2 consecutive downtrend days

Momentum

RSI (14)

43.7
OversoldNeutralOverbought

MACD

Line

-0.01

Signal

-0.00

Histogram

-0.00

Stochastic %K

30.4
OversoldNeutralOverbought
%D (Signal)37.7
Volatility

Bollinger Bands

Upper

1.26

Middle

1.20

Lower

1.14

1.141.26

ATR (14)

Value

0.05

%

4.56%

Volume

Relative Volume

0.2xBelow average
0.5x1.0x1.5x+

OBV Trend

Distribution

OBV < SMA 20

Fundamentals

Financials

Revenue

1.4B

+27.98% YoY+0.00% QoQ

Net Income

61.8M

+338.86% YoY+0.00% QoQ

Free Cash Flow

142.5M

-12.10% YoY

Gross Margin

41.04%

Operating Margin

-

Net Margin

4.56%

FCF Margin

10.51%
Quarterly Results
Annual Results

Dividends

Yield (TTM)

0.00%

Annual Dividend

-

Payout Ratio

0.00%

Track Record

-

Dividend History

Peer Comparison

CompanyPriceChangeP/E RatioMarket CapDividend Yield

Pure Health Holding PJSC

AED 2.59+0.78%4.0528.8B1.19%

BURJEEL HOLDINGS PLC

AED 1.29-1.53%4.616.7B2.33%
GMPCADX

Gulf Medical Projects Company

AED 1.93-0.52%3.321.3B7.77%
RPMADX

Response Plus Holding PrJSC

AED 3.10+0.00%3.15620.0M6.13%

About

Julphar is one of the largest pharmaceutical manufactures in the Middle East and Africa and one of the leading producers of insulin in the world. The company was established in 1980 under the guidance of Sheikh Saqr Bin Mohammed Al Qasimi, the late ruler of Ras Al Khaimah, and since then Julphar has been delivering high quality, innovative and affordable healthcare solutions to families across the globe.Our business is centred around General Medicines in the retail pharmacy channel and hospitals as well as speciality Products, Our medicines target major therapeutic segments including Diabetes, Gastrointestinal Tract (GIT), Respiratory, Pain Management, Wounds and Scars, Anti-infectives, Anemia, Gynecology, Dermatology, Erectile Dysfunction and Cardiology.We employ around 3,400 people and distribute our products to more than 30 countries on five continents. Our 12 internationally accredited manufacturing facilities can produce up to half million boxes of medicine a day. In 2012, we became one of the world’s largest producers of insulin, driven by our advanced biotechnology facilities in the UAE.

Sector

Health Care

ISIN

AEG000201018

Listed

Oct 20, 2002

Auditor

KPMG

Board of Directors

Shaikh Saqer Humaid Abdulla Alqasemi

Chairman

Jean Maroun Diab

Vice Chairman

Basel Nimer Ali Ziyadeh

CE/ CEO

Management

Juergen Wolfgang Lauterbach

Top Management

Malik Metahri

Top Management

Khalid Zuhair Abdullah Malkawi

Top Management

Alaa Abdelghany Mohamed Gamaleldin

Top Management

Gopa Kumar Gopalakrishnan Nair

Top Management

Malek Ben Ezzeddine Aloui

Board Secretary

Contact